Revised Guidance Document on Developing and Assessing Adverse Outcome Pathways
ثبت نشده
چکیده
منابع مشابه
Four forward-looking guidance points.
Four key guidance points in the UNAIDS guidance document, Ethical Considerations in HIV Preventive Vaccine Research, are compared with analogous statements in three other recently issued documents dealing with international research. Those documents are: the Declaration of Helsinki, as revised in 2000; the report of the U.S. National Bioethics Advisory Commission, issued in 2001; and a current ...
متن کاملMapping of McGraw Cycle to RUP Methodology for Secure Software Developing
Designing a secure software is one of the major phases in developing a robust software. The McGraw life cycle, as one of the well-known software security development approaches, implements different touch points as a collection of software security practices. Each touch point includes explicit instructions for applying security in terms of design, coding, measurement, and maintenance of softwar...
متن کاملERDC/EL TR-13-11 "Hydrogeomorphic (HGM) Approach to Assessing Wetland Functions: Guidelines for Developing Guidebooks (Version 2)"
The Hydrogeomorphic (HGM) Approach for assessing wetlands was developed by the U.S. Army Corps of Engineers as a procedure for assessing the capacity of a wetland to perform ecological functions. The Approach requires classification of wetlands based on geomorphic setting, water source, and hydrodynamics. The objective of the Guidelines for Guidebook Development is to provide detailed guidance ...
متن کاملGuidance on Topical Anesthetics
This guidance is based on the best clinical evidence currently available. The recommendations in this document are dynamic, and will be revised as new clinical information becomes available. This guidance is intended to assist practitioners in providing consistent, high quality, cost effective drug therapy. These criteria are not intended to interfere with clinical judgment. The clinician must ...
متن کاملPatient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index.
We describe the progress towards developing a patient rated toxicity index that meets all of the patient-important attributes defined by the OMERACT Drug Safety Working Party. These attributes are frequency, severity, importance to patient, importance to the clinician, impact on economics, impact on activities, and integration of adverse effects with benefits. The Stanford Toxicity Index (STI) ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2017